MCBI
MCBI is a company dedicated to exploring biomarkers for preemptive medicine, aiming to realize a society where people can live healthily and happily. They focus on early detection and prevention of diseases, especially dementia, through research and development of blood-based biomarkers and genetic testing. Their mission is to support individuals in living healthy and happy lives by advancing early diagnosis and preventive healthcare.
Industries
Nr. of Employees
small (1-50)
MCBI
102-0072 Tokyo, Chiyoda-ku, Iidabashi 2-14-7, Hikari Building 4F
Patents
Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
US-11726099-B2
View DetailsBiomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker
US-11543418-B2
View DetailsBiomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers
US-11307208-B2
View DetailsBiomarker for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
US-8748574-B2
View Details
Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
US-11726099-B2
View DetailsBiomarker for cognitive dysfunction disease and method for detecting cognitive dysfunction disease using biomarker
US-11543418-B2
View DetailsBiomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers
US-11307208-B2
View DetailsBiomarker for psychiatric diseases including cognitive impairment and methods for detecting psychiatric diseases including cognitive impairment using the biomarkers
US-8748574-B2
View DetailsProducts
MCI screening blood test (multi‑protein LC‑MS panel)
Laboratory test that quantifies a set of blood proteins related to Alzheimer’s-type pathology to estimate risk of mild cognitive impairment (MCI) and track changes over time.
APOE genotype test
Genetic test to determine APOE allele combinations (e.g., ε2/ε3/ε4) used to assess relative genetic susceptibility to Alzheimer’s disease and related treatment risk considerations.
MCI screening blood test (multi‑protein LC‑MS panel)
Laboratory test that quantifies a set of blood proteins related to Alzheimer’s-type pathology to estimate risk of mild cognitive impairment (MCI) and track changes over time.
APOE genotype test
Genetic test to determine APOE allele combinations (e.g., ε2/ε3/ε4) used to assess relative genetic susceptibility to Alzheimer’s disease and related treatment risk considerations.
Services
Clinical laboratory service that measures a multi‑protein blood panel to evaluate MCI/cognitive decline risk and provide longitudinal risk tracking.
Genetic testing service to determine APOE genotype for assessment of lifetime Alzheimer's disease risk and treatment‑related risk considerations.
Collaborative research service offering study design, biomarker measurement, data analysis and interpretation to evaluate efficacy of products or programs (e.g., beverages, supplements, exercise).
Provision of educational materials, web content and community prevention classes to increase public understanding of dementia and actionable prevention measures.
Operational support for clinical studies including participant recruitment, site coordination, sample logistics, and interactions with clinical research coordinators.
Clinical laboratory service that measures a multi‑protein blood panel to evaluate MCI/cognitive decline risk and provide longitudinal risk tracking.
Genetic testing service to determine APOE genotype for assessment of lifetime Alzheimer's disease risk and treatment‑related risk considerations.
Collaborative research service offering study design, biomarker measurement, data analysis and interpretation to evaluate efficacy of products or programs (e.g., beverages, supplements, exercise).
Provision of educational materials, web content and community prevention classes to increase public understanding of dementia and actionable prevention measures.
Operational support for clinical studies including participant recruitment, site coordination, sample logistics, and interactions with clinical research coordinators.
Expertise Areas
- Biomarker discovery and validation
- Blood‑based diagnostics and proteomics
- Clinical trial design and longitudinal study execution
- Effect measurement for preventive interventions
Key Technologies
- Liquid chromatography–mass spectrometry (LC‑MS)
- Proteomic multi‑protein biomarker panels
- Genotyping (APOE)
- Functional near‑infrared spectroscopy (fNIRS)